Association for Accessible Medicines

09/25/2025

Comprising only 1.2 percent of total U.S. healthcare spending in 2024, generic medicines saved American’s $467 billion—providing patients the health and financial outcomes necessary to thrive. https://accessiblemeds.org/resources/blog/2025-savingsreport

09/22/2025

Generic medicines give America's patients the confidence to thrive! Last year, comprised 90% of all prescriptions filled, but only 12% of prescription spending. In sharp contrast, brand drugs supported patients less often— making up only 10% of prescriptions filled but adding up to 88% of the total drug spend. Learn more about what makes generic medicines unique in AAM’s : https://accessiblemeds.org/resources/blog/2025-savings-report

09/19/2025

A decade after the first entered to the U.S. market, $56.2 billion have been saved by the healthcare system and 3.3 billion additional days of patient care have been possible. But due to harmful policies that impeded biosimilar uptake, we are currently experiencing a biosimilar void. Policymakers must ACT NOW to safeguard enormous benefits to Americans—$20.2 billion in 2024, alone. MORE: https://accessiblemeds.org/resources/blog/2025-savings-report

09/17/2025

In 2024, & saved America’s patients and the U.S. healthcare system $467 billion—and $3.4 trillion in the past 10 years. Learn more, including what can be done to help safeguard this important industry: https://accessiblemeds.org/resources/blog/2025-savings-report

09/16/2025

Explore the Future of + at 2025 Expo. Join our 2-hour interactive session with FDA experts from OGD, OPQ, OTBB and more. Connect, collaborate, and grow your expertise. Register today: https://grxbiosims.org

09/11/2025

In the past decade, and medicines have saved the U.S. healthcare system $3.4 trillion. Still, threats to the sustainability of this essential industry remain. Policymakers must ACT NOW to streamline FDA processes, curb patent abuse, stop PBMs and Medicare policies from denying patient access, and rollback harmful federal policies – including IRA price controls – to safeguard the livelihood of America’s patients. Learn more in the : https://accessiblemeds.org/resources/blog/2025-savings-report

09/03/2025

The Association for Accessible Medicines and the Biosimilars Council today released the 2025 U.S. Generic & Biosimilar Medicines Savings Report. AAM’s annual savings report highlights that generic and biosimilar medicines created $467 billion in savings in 2024 for patients and the overall healthcare system. Generics and biosimilars have saved over $3.4 trillion in the last decade.

Learn More: https://accessiblemeds.org/resources/blog/2025-savings-report/

08/27/2025

Mark your calendar for February 23–25, 2026, and join at the JW Marriott Miami Turnberry Resort & Spa for a can’t-miss event bringing together top minds from across the generics and biosimilars industry.

Whether you're a seasoned expert or emerging leader, this is your chance to gain fresh insights, make valuable connections, and be part of critical conversations shaping the future.

Register by September 20, 2025, to take advantage of our early bird discount and lock in your place at a reduced rate. https://access.accessiblemeds.org

08/27/2025

Wise guidance to ensure more affordable medicines are always available for America’s patients, from President & CEO, John Murphy III

Biosimilars Council

READ:

In July, when President Trump fired off letters to 17 of the world’s largest drug manufacturers demanding most favored nation prices in the United States within 60 days and threatening tariffs as high as 200%, he put the right headline on the wrong prescription.

08/25/2025

At 2025, join Ronald T. Piervincenzi, CEO of US Pharmacopeia, and John Murphy III, President of AAM, for a powerful fireside chat on global medicine quality, regulatory collaboration, and building a more resilient supply of generics and biosimilars.

Gain insights into how USP is partnering across sectors to tackle quality challenges and support smarter decision-making worldwide.

Reserve your spot now! https://grxbiosims.org

08/05/2025

Our AAM team strives to improves patient access to safe, quality and effective medicines.

Working to get more-affordable generic and biosimilar medicines out of the labs and into the hands of the people who need them is a goal that touches not just individuals and families, but the overall economy and security of America.

As manufacturers of 9 out of every 10 prescriptions filled in the U.S., AAM member companies serve as the foundation of our healthcare system -- with a combined 80 locations across the U.S., alone!

Learn More: https://accessiblemeds.org/about/

07/29/2025

Imposing on and medicines heightens market sustainability concerns and potentially exacerbates supply chain shortages. This could be devastating for people being treated for common conditions like diabetes, cancer and heart disease—people who depend on low-cost medications to survive😢

The negative effects of tariffs include:
- Triggering unprecedented drug shortages for America's patients
- Raising prices on the most affordable prescription drugs - which also make up 90 percent of all prescriptions filled - in the U.S. market

Get the Facts:https://accessiblemeds.org/wp-content/uploads/2025/02/AAM-tariff-actions-should-ensure-access-to-lower-cost-generic-and-biosimilar-medicines.pdf